Trial Profile
Study of CA19-9 as a predictive marker for early efficacy of Regorafenib in refractory metastatic colorectal cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2018
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 12 Mar 2018 New trial record